[HTML][HTML] Rilotumumab resistance acquired by intracrine hepatocyte growth factor signaling
F Cecchi, K Rex, J Schmidt, CD Vocke, YH Lee… - Cancers, 2023 - mdpi.com
Simple Summary Drug resistance is a long-standing impediment to effective systemic cancer
therapy and acquired drug resistance is a growing problem for new therapeutics that …
therapy and acquired drug resistance is a growing problem for new therapeutics that …
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
F Cecchi, K Rex, J Schmidt, CD Vocke, YH Lee… - …, 2023 - search.proquest.com
Drug resistance is a long-standing impediment to effective systemic cancer therapy and
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
F Cecchi, K Rex, J Schmidt, CD Vocke, YH Lee… - …, 2023 - search.ebscohost.com
Abstract Simple Summary: Drug resistance is a long-standing impediment to effective
systemic cancer therapy and acquired drug resistance is a growing problem for new …
systemic cancer therapy and acquired drug resistance is a growing problem for new …
[HTML][HTML] Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
F Cecchi, K Rex, J Schmidt, CD Vocke, YH Lee… - Cancers, 2023 - ncbi.nlm.nih.gov
Drug resistance is a long-standing impediment to effective systemic cancer therapy and
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling
F Cecchi, K Rex, J Schmidt, CD Vocke, YH Lee… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Drug resistance is a long-standing impediment to effective systemic cancer therapy and
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
F Cecchi, K Rex, J Schmidt, CD Vocke, YH Lee… - Cancers, 2023 - europepmc.org
Drug resistance is a long-standing impediment to effective systemic cancer therapy and
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …
acquired drug resistance is a growing problem for molecularly-targeted therapeutics that …